Aclaris Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Aclaris Therapeutics, Inc. holds 34 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 24 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include KINECT, THWART, ACLARIS, RHOFADE, and CONFLUENCE. The owner is based in Wayne, PA.
640 Lee Road, Suite 200
Wayne, PA 19087
Showing of trademarks Trademarks
Trademark Classifications
Aclaris Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Aclaris Therapeutics, Inc. have?
Aclaris Therapeutics, Inc. has 34 U.S. trademarks filed with the USPTO. Of these, 8 registered, 22 abandoned, 4 cancelled.
What trademark classes does Aclaris Therapeutics, Inc. file in?
Aclaris Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Aclaris Therapeutics, Inc.'s most well-known trademarks?
Aclaris Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as KINECT, THWART, ACLARIS, RHOFADE, and CONFLUENCE. These are among 8 currently registered trademarks in the portfolio.
What is Aclaris Therapeutics, Inc.'s trademark registration success rate?
Aclaris Therapeutics, Inc. has a 24% trademark registration rate, with 8 out of 34 resolved applications resulting in successful registration. Currently, 0 applications are pending review.